-
Aug 02, 2018
Avelas Biosciences Initiates Period 2 of Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery
Read more
-
Jun 14, 2018
Avelas Biosciences to Present at JMP Securities Annual Life Sciences Conference
Read more
-
Mar 21, 2018
Avelas Biosciences to Present at Needham & Company 17th Annual Healthcare Conference
Read more
-
Mar 13, 2018
Avelas Biosciences to Present at Oppenheimer 28th Annual Healthcare Conference
Read more
-
Jan 04, 2018
Avelas Biosciences Completes Period 1 Patient Enrollment in Phase 2 Study of AVB-620 in Women with Primary, Nonrecurrent Breast Cancer Undergoing Surgery
Read more
-
Jan 03, 2018
Avelas Biosciences Broadens Management Team with Key Executive Additions
Read more
-
Nov 21, 2017
Avelas Biosciences to Present at Piper Jaffray Healthcare Conference
Read more
-
Sep 26, 2017
Newly Published Data Supports Avelas Biosciences’ Investigational Ratiometric Activatable Fluorescent Peptide AVB-620 in Intraoperative Tumor Detection
Read more
-
Sep 14, 2017
Avelas Biosciences’ AVB-620 Shows Sensitive In Vivo Visualization of Breast Cancer in Journal Publication
Read more
« Previous Page — Next Page »
